SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | 4:持股变动声明-高管 Bausch Christoph Lawrence
SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | 4:持股变动声明-高管 Kropotova Alexandra
SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | 4:持股变动声明-高管 Sullivan Eddie Joe
SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | 4:持股变动声明-高管 King Michael
SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | 4:持股变动声明-高管 Reich Samuel J
SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | SC 13G/A:超过5%持股股东披露文件(修正)-Commodore Capital LP(3.5%),Commodore Capital Master LP(3.5%)
SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | SC 13G:超过5%持股股东披露文件-RTW Investments, LP(9.99%),Roderick Wong, M.D.(9.99%)
SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | SC 13G/A:超过5%持股股东披露文件(修正)-Radcliffe Capital Management, L.P.(0.00%),RGC Management Company, LLC(0.00%)等
SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | 4:持股变动声明-首席执行官 Sullivan Eddie Joe
SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | SC 13G:超过5%持股股东披露文件-BVF Partners L.P.(9.99%),BVF Inc.(9.99%)等
SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | 4:持股变动声明-首席财务官 King Michael
SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | 4:持股变动声明-董事会执行主席 Reich Samuel J
SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | 4:持股变动声明-董事 Sessa Capital (Master), L.P.
SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | 4:持股变动声明-董事 Moin Andrew
SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | 4:持股变动声明-董事 Ellias Helen K.
SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | 3:首次持股声明-董事 Ellias Helen K.
SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | 4/A:持股变动声明(修正)-董事 Moin Andrew
SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | 4/A:持股变动声明(修正)-董事 Sessa Capital (Master), L.P.
SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | 4:持股变动声明-董事 Moin Andrew
SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | 4:持股变动声明-董事 Sessa Capital (Master), L.P.
暂无数据